<DOC>
	<DOCNO>NCT01300533</DOCNO>
	<brief_summary>The goal Phase 1 clinical research study find high safe dose BIND-014 give treatment patient advance metastatic cancer .</brief_summary>
	<brief_title>A Study BIND-014 Given Patients With Advanced Metastatic Cancer</brief_title>
	<detailed_description>The study design explore safety , tolerability , pharmacokinetics pharmacodynamics BIND-014 define recommend Phase 2 dose BIND-014 . All cycle therapy consist patient take BIND-014 intravenously every three week weekly three four week .</detailed_description>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Neoplasms , Second Primary</mesh_term>
	<criteria>1 . Signed informed consent form . ( ICF ) 2 . At least 18 year old . 3 . Patients histologically cytologically confirm advanced metastatic cancer standard curative therapy exists . 4 . Measurable evaluable disease per RECIST version 1.1 . 5 . Eastern Cooperative Oncology Group Performance Status ( ECOG ) 0 1 . 6 . Life expectancy great 12 week . 7 . Female subject eligible enter participate study : 1 . Nonchildbearing potential ( i.e. , physiologically incapable become pregnant ) include woman : Has hysterectomy , Has bilateral oophorectomy ( ovariectomy ) , Has bilateral tubal ligation , Is postmenopausal ( demonstrated total cessation menses least 1 year ) . 2 . Childbearing ( CB ) potential , long negative serum pregnancy test screen followup , agree one following : Use intrauterine device ( IUD ) document failure rate le 1 % per year . Use double barrier contraception method define condom spermicidal jelly , foam , suppository , film ; OR diaphragm spermicide ; OR male condom diaphragm . The woman 's sole male sexual partner vasectomize male sterile prior subject 's entry study . 1 . Brain metastasis spinal cord compression , unless treatment complete least 4 week entry , stable without steroid treatment least 4 week . 2 . Inadequate bone marrow reserve demonstrate absolute neutrophil count ( ANC ) &lt; 1.5 x 10^9/L platelet count &lt; 100 x 10^9/L ( posttransfusion ) hemoglobin &lt; 9 g/dL ( posttransfusion ) . 3 . Serum bilirubin &gt; 1.2 time upper limit normal ( ULN ) . 4 . An alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) level &gt; 1.5 x ULN alkaline phosphatase &gt; 2.5 x ULN . 5 . Serum creatinine &gt; 1.5 x ULN creatinine clearance &lt; 50 mL/min calculate CockcroftGault . 6 . Evidence severe uncontrolled systemic disease ( e.g. , unstable uncompensated respiratory , cardiac [ include lifethreatening arrhythmias ] , hepatic , renal disease ) . 7 . Unresolved toxicity â‰¥ Common Toxicity Criteria ( CTC ) grade 2 previous anticancer therapy except alopecia ( applicable ) unless agree patient enter discussion Medical Monitor . 8 . QTc prolongation define QTc Framingham correction great equal 470 m prior history arrhythmia significant electrocardiogram ( ECG ) abnormality . Certain condition acceptable ( e.g. , control atrial fibrillation ) agree Medical Monitor . 9 . Participation study investigational agent within 30 day prior screen . 10 . Having receive treatment cancer ( include chemotherapy , surgery and/or radiation ) within 30 day prior screen . 11 . Pregnant breastfeeding female . 12 . Men father potential must use adequate method contraception avoid conception throughout study ( 26 week last dose investigational product ) manner risk pregnancy minimize 13 . Peritoneal pleural effusion require tap frequently every 14 day . 14 . Any concurrent condition , Investigator 's opinion , make undesirable subject participate study would jeopardize compliance protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Cancer</keyword>
	<keyword>Neoplasms</keyword>
	<keyword>Solid Tumor</keyword>
	<keyword>Ovarian Cancer</keyword>
	<keyword>Lung Cancer</keyword>
	<keyword>Non-Small Cell Lung Cancer</keyword>
	<keyword>Pancreatic Cancer</keyword>
	<keyword>Breast Cancer</keyword>
	<keyword>Endometrial Cancer</keyword>
	<keyword>Melanoma</keyword>
	<keyword>Prostate Cancer</keyword>
	<keyword>Skin Cancer</keyword>
	<keyword>Head Neck Cancer</keyword>
	<keyword>Solid Malignancies</keyword>
</DOC>